131 related articles for article (PubMed ID: 38530480)
21. The Effect of Treatment Intensification on Other-Cause Mortality in Clear-Cell Metastatic Renal Cell Carcinoma Patients.
Incesu RB; Barletta F; Garcia CC; Scheipner L; Morra S; Baudo A; Assad A; Tian Z; Saad F; Shariat SF; Carmignani L; Longo N; Ahyai S; Chun FKH; Briganti A; Tilki D; Graefen M; Karakiewicz PI
Clin Genitourin Cancer; 2024 Apr; 22(2):420-425. PubMed ID: 38307818
[TBL] [Abstract][Full Text] [Related]
22. The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size ≤4 cm.
Tappero S; Barletta F; Piccinelli ML; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Parodi S; Dell'Oglio P; Palumbo C; Briganti A; De Cobelli O; Chun FKH; Graefen M; Longo N; Ahyai S; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
Eur Urol Focus; 2023 Sep; 9(5):742-750. PubMed ID: 36906483
[TBL] [Abstract][Full Text] [Related]
23. Radical versus partial nephrectomy: effect on overall and noncancer mortality.
Zini L; Perrotte P; Capitanio U; Jeldres C; Shariat SF; Antebi E; Saad F; Patard JJ; Montorsi F; Karakiewicz PI
Cancer; 2009 Apr; 115(7):1465-71. PubMed ID: 19195042
[TBL] [Abstract][Full Text] [Related]
24. Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib-II renal masses: An analysis of the national cancer data base.
Ristau BT; Handorf EA; Cahn DB; Kutikov A; Uzzo RG; Smaldone MC
Cancer; 2018 Oct; 124(19):3839-3848. PubMed ID: 30207380
[TBL] [Abstract][Full Text] [Related]
25. Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project).
Mir MC; Pavan N; Capitanio U; Antonelli A; Derweesh I; Rodriguez-Faba O; Linares E; Takagi T; Rha KH; Fiori C; Maurer T; Zang C; Mottrie A; Umari P; Long JA; Fiard G; De Nunzio C; Tubaro A; Tracey AT; Ferro M; De Cobelli O; Micali S; Bevilacqua L; Torres J; Schips L; Castellucci R; Dobbs R; Quarto G; Bove P; Celia A; De Concilio B; Trombetta C; Silvestri T; Larcher A; Montorsi F; Palumbo C; Furlan M; Bindayi A; Hamilton Z; Breda A; Palou J; Aguilera A; Tanabe K; Raheem A; Amiel T; Yang B; Lima E; Crivellaro S; Perdona S; Gregorio C; Barbati G; Porpiglia F; Autorino R
World J Urol; 2020 Jan; 38(1):151-158. PubMed ID: 30937569
[TBL] [Abstract][Full Text] [Related]
26. A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma.
Bianchi M; Gandaglia G; Trinh QD; Hansen J; Becker A; Abdollah F; Tian Z; Lughezzani G; Roghmann F; Briganti A; Montorsi F; Karakiewicz PI; Sun M
Urol Oncol; 2014 Jan; 32(1):46.e1-7. PubMed ID: 24054864
[TBL] [Abstract][Full Text] [Related]
27. Cancer-specific and non-cancer-related mortality rates in European patients with T1a and T1b renal cell carcinoma.
Zini L; Patard JJ; Capitanio U; Crepel M; de La Taille A; Tostain J; Ficarra V; Bernhard JC; Ferrière JM; Pfister C; Villers A; Montorsi F; Karakiewicz PI
BJU Int; 2009 Apr; 103(7):894-8. PubMed ID: 19076131
[TBL] [Abstract][Full Text] [Related]
28. Radical Versus Partial Nephrectomy for cT1 Renal Cell Carcinoma.
Gershman B; Thompson RH; Boorjian SA; Lohse CM; Costello BA; Cheville JC; Leibovich BC
Eur Urol; 2018 Dec; 74(6):825-832. PubMed ID: 30262341
[TBL] [Abstract][Full Text] [Related]
29. Renal Cell Carcinoma: Comparison between Variant Histology and Clear Cell Carcinoma across All Stages and Treatment Modalities.
Deuker M; Stolzenbach F; Rosiello G; Palumbo C; Martin T; Tian Z; Chun FK; Saad F; Shariat SF; Kapoor A; Karakiewicz PI
J Urol; 2020 Oct; 204(4):671-676. PubMed ID: 32250728
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic Body Radiotherapy for Stage I Renal Cell Carcinoma: National Treatment Trends and Outcomes Compared to Partial Nephrectomy and Thermal Ablation.
Uhlig A; Uhlig J; Trojan L; Kim HS
J Vasc Interv Radiol; 2020 Apr; 31(4):564-571. PubMed ID: 32127324
[TBL] [Abstract][Full Text] [Related]
31. Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma.
Marchioni M; Harmouch SS; Nazzani S; Bandini M; Preisser F; Tian Z; Kapoor A; Cindolo L; Briganti A; Shariat SF; Schips L; Karakiewicz PI
Cancer Epidemiol; 2018 Jun; 54():112-118. PubMed ID: 29715680
[TBL] [Abstract][Full Text] [Related]
32. The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT
Marchioni M; Bandini M; Pompe RS; Martel T; Tian Z; Shariat SF; Kapoor A; Cindolo L; Briganti A; Schips L; Capitanio U; Karakiewicz PI
BJU Int; 2018 Mar; 121(3):383-392. PubMed ID: 28940649
[TBL] [Abstract][Full Text] [Related]
33. Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients.
Parker WP; Cheville JC; Frank I; Zaid HB; Lohse CM; Boorjian SA; Leibovich BC; Thompson RH
Eur Urol; 2017 Apr; 71(4):665-673. PubMed ID: 27287995
[TBL] [Abstract][Full Text] [Related]
34. Comparison of prognosis between patients undergoing radical nephrectomy versus partial nephrectomy for renal cell carcinoma ≤7 cm T3aN0/xM0: Survival benefit is biased toward partial nephrectomy.
Liu S; Feng C; Liu C; Wang Z
Cancer Med; 2021 Dec; 10(24):8909-8923. PubMed ID: 34779154
[TBL] [Abstract][Full Text] [Related]
35. Race/Ethnicity Determines Life Expectancy in Surgically Treated T1aN0M0 Renal Cell Carcinoma Patients.
Würnschimmel C; Collà Ruvolo C; Nocera L; Wenzel M; Tian Z; Saad F; Briganti A; Shariat SF; Mirone V; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
Eur Urol Focus; 2022 Jan; 8(1):191-199. PubMed ID: 33610487
[TBL] [Abstract][Full Text] [Related]
36. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
[TBL] [Abstract][Full Text] [Related]
37. Preserving Renal Function through Partial Nephrectomy Depends on Tumor Complexity in T1b Renal Tumors.
Yoo S; You D; Jeong IG; Hong B; Hong JH; Kim CS; Ahn H; Song C
J Korean Med Sci; 2017 Mar; 32(3):495-501. PubMed ID: 28145654
[TBL] [Abstract][Full Text] [Related]
38. Survival benefit stratification of partial nephrectomy versus non-surgical treatment in elderly patients with T1a renal cell carcinoma.
Tang Y; Wu K; Hu X; Liu Y; Yang W; Li X
Cancer Med; 2023 Apr; 12(7):7974-7981. PubMed ID: 36629133
[TBL] [Abstract][Full Text] [Related]
39. Comparative Effectiveness of Thermal Ablation, Surgical Resection, and Active Surveillance for T1a Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked Population Study.
Xing M; Kokabi N; Zhang D; Ludwig JM; Kim HS
Radiology; 2018 Jul; 288(1):81-90. PubMed ID: 29737950
[TBL] [Abstract][Full Text] [Related]
40. Percutaneous Ablation Versus Partial and Radical Nephrectomy for T1a Renal Cancer: A Population-Based Analysis.
Talenfeld AD; Gennarelli RL; Elkin EB; Atoria CL; Durack JC; Huang WC; Kwan SW
Ann Intern Med; 2018 Jul; 169(2):69-77. PubMed ID: 29946703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
